There are currently 99 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Autism participants are New York, Texas, California and Ohio.
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT05559879
Recruiting
Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of a... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama
Conditions: Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
Register for Updates
First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies
NCT05123482
Recruiting
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2023
Locations: Research Site, Duarte, California +52 locations
Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Carcinoma
Register for Updates
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT03835819
Recruiting
This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: mirvetuximab soravtansine (IMGN853) pembrolizumab
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Endometrial Cancer
Register for Updates
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT02922764
Recruiting
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Arizona Oncology, Tucson, Arizona +20 locations
Conditions: Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
Register for Updates
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272
Recruiting
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced sol... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona +18 locations
Conditions: Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Register for Updates
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT03832361
Recruiting
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Gender:
Female
Ages:
Between 18 years and 100 years
Trial Updated:
11/08/2023
Locations: Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut
Conditions: Endometrial Cancer
Register for Updates
De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NCT04386993
Recruiting
The goal of this study is to evaluate short course radiation in the post-operative female pelvis after hysterectomy in stage III-IVA endometrial adenocarcinoma patients, or any stage patients with uterine serous or carcinosarcoma histology. The investigators hypothesize that short course pelvic radiation will have an acute and late grade 3-4 toxicity rate < 10%, and patients will benefit from both convenient and effective loco-regional control comparable to the traditional 5-6 weeks of radiation... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Endometrial Cancer
Register for Updates
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT05500508
Recruiting
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/18/2023
Locations: Mayo Clinic - Arizona, Phoenix, Arizona +6 locations
Conditions: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Register for Updates
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT06096688
Recruiting
The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or endometrial cancer at NYPH and WCM for routine clinical care and to make these available for future use for molecular and mechanistic studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: NYP/Weill Cornell Medicine, New York, New York
Conditions: Colorectal Cancer, Endometrial Cancer, Hereditary Cancer Syndromes
Register for Updates
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
NCT03876860
Recruiting
This is a randomized control trial aimed to decreased radiation-induced vaginal stenosis in patients with endometrial or cervical cancer treated with post-operative external beam radiation therapy with or without brachytherapy. The intervention is an enhanced vaginal dilator model, including a silicone band placed at the desired depth of dilator insertion. The new model will be compared against the traditional vaginal dilator model used as our institutional standard of care. We hypothesize the e... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/03/2023
Locations: Loyola University Medical Center, Maywood, Illinois
Conditions: Endometrial Cancer, Cervical Cancer, Vaginal Stricture, Radiation Toxicity
Register for Updates
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT04080284
Recruiting
Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patients with advanced or platinum sensitive recurrent uterine serous carcinoma. Additionally, the investigators aim to further describe the safety of this regimen. The investigators hypothesize that Nirap... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
09/20/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +4 locations
Conditions: Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma, Cancer of the Endometrium
Register for Updates
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
NCT05655598
Recruiting
The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: Patients with advanced breast cancer that has become worse after taking palbociclib alone Patients with cancers that have an abnormality in a gene called the "retinoblastoma gene".
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Lifespan Cancer Institute, Providence, Rhode Island
Conditions: Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer
Register for Updates